⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11702505 | 0.90 | NOS2 (0.32) | — | |
| SCHEMBL749590 | 0.87 | EPHX2 (0.40) | — | |
| SCHEMBL404198 | 0.87 | EPHX2 (0.40) | — | |
| SCHEMBL752775 | 0.87 | EPHX2 (0.40) | — | |
| SCHEMBL216556 | 0.86 | — | — | |
| SCHEMBL217137 | 0.86 | — | — | |
| SCHEMBL754013 | 0.85 | NOS2 (0.35) | — | |
| SCHEMBL751411 | 0.85 | NOS2 (0.35) | — | |
| SCHEMBL751410 | 0.85 | NOS2 (0.35) | — | |
| SCHEMBL11699976 | 0.85 | EPHX1 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2059 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4389738-A1 | SOS1 INHIBITOR AND USE THEREOF | Kanaph Therapeutics Inc. (KR) | 2024-06-26 | — | — | EP | claimed |
| US-12018021-B2 | Thiophene derivatives for the treatment of disorders caused by IgE | UCB Biopharma SRL (BE) | 2024-06-25 | — | — | US | claimed |
| CN-118119600-A | SOS1 inhibitors and uses thereof | 治纳辅医药科技有限公司 | 2024-05-31 | — | — | CN | claimed |
| CN-118084932-A | Celastracene compound and use thereof | 台湾卫生研究院 | 2024-05-28 | — | — | CN | claimed |
| WO-2024068519-A1 | 3-(HETERO)ARYL-5-CHLORODIFLUOROMETHYL-1,2,4-OXADIAZOLE AS FUNGICIDE | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-04 | — | — | WO | claimed |
| WO-2024068520-A1 | 3-(HETERO)ARYL-5-CHLORODIFLUOROMETHYL-1,2,4-OXADIAZOLE AS FUNGICIDE | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-04 | — | — | WO | claimed |
| CN-114507181-B | Propionic acid compound containing 5-substituted tetrahydroisoquinoline, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2024-03-26 | — | — | CN | claimed |
| CN-117736177-A | Propionic acid compound containing (R) -5-substituted tetrahydroisoquinoline, preparation method and medical application thereof | 中国医学科学院药物研究所 | 2024-03-22 | — | — | CN | claimed |
| WO-2023213882-A1 | IRREVERSIBLE MUTEGFR INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-11-09 | — | — | WO | claimed |
| CN-116969925-A | Heteroaryl-triazole compounds | 拜耳公司 | 2023-10-31 | — | — | CN | claimed |
| EP-0495091-A4 | AICA RIBOSIDE ANALOGS | — | 1993-01-07 | — | — | EP | claimed |
| EP-0495091-A1 | AICA RIBOSIDE ANALOGS | GENSIA, INC. (US) | 1992-07-22 | — | — | EP | claimed |
| WO-1992002213-A1 | METHODS OF PREVENTING OR DECREASING TISSUE DAMAGE BY NOVEL ANTIOXIDANTS AND FREE RADICAL SCAVENGERS | GENSIA PHARMACEUTICALS, INC. (US) | 1992-02-20 | — | — | WO | claimed |
| WO-1992002214-A1 | AICA RIBOSIDE ANALOGS | GENSIA PHARMACEUTICALS, INC. (US) | 1992-02-20 | — | — | WO | claimed |
| EP-0428365-A1 | Aminomacrolides and derivatives having immunosuppressive activity | MERCK & CO. INC. (US) | 1991-05-22 | — | — | EP | claimed |
| EP-0398059-A1 | Cyclopropanoylaminoacid amide derivatives | BAYER AG (DE) | 1990-11-22 | — | — | EP | claimed |
| EP-0123254-B1 | TRIAZINE DERIVATIVES, PROCESSES FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1988-06-22 | — | — | EP | claimed |
| US-4684731-A | NEUROLEPTIC, ANTIEMETIC, ANALGESIC | HOFFMANN-LA ROCHE INC. (US) | 1987-08-04 | — | — | US | claimed |
| EP-0037990-B1 | PHENYL QUINOLIZIDINES, CORRESPONDING PHARMACEUTICAL PREPARATIONS, THE PREPARATION OF THE ACTIVE COMPOUNDS AND CORRESPONDING STARTING COMPOUNDS | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1984-12-05 | — | — | EP | claimed |
| EP-0037990-A1 | Phenyl quinolizidines, corresponding pharmaceutical preparations, the preparation of the active compounds and corresponding starting compounds | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1981-10-21 | — | — | EP | claimed |